Chlamydia infection screening

Revision as of 16:20, 8 September 2016 by Aysha Aslam (talk | contribs)
Jump to navigation Jump to search

Sexually transmitted diseases Main Page

Chlamydia infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

C. trachomatis
Other Chlamydiae

Differentiating Chlamydia Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chlamydia infection screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chlamydia infection screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chlamydia infection screening

CDC on Chlamydia infection screening

Chlamydia infection screening in the news

Blogs on Chlamydia infection screening

Directions to Hospitals Treating Chlamydia infection

Risk calculators and risk factors for Chlamydia infection screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maliha Shakil, M.D. [2] Aysha Anwar, M.B.B.S[3]

Overview

According to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC, screening for chlamydia is recommended for sexually active women under 25 years, women over 25 who are at increased risk, all pregnant women under 25 years, pregnant women over 25 who are at increased risk, men who have sex with men, and individuals with HIV.[1][2]

Screening

According to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC, screening for chlamydia is recommended. The guidelines are as follows:[1]</ref>[2]

Women

  • Sexually active women under 25 years of age.
  • Sexually active women aged 25 years and older if at increased risk.
  • Retest approximately 3 months after treatment.

Pregnant Women

  • All pregnant women under 25 years of age.
  • Pregnant women, aged 25 and older if at increased risk.
  • Retest during the 3rd trimester for women under 25 years of age or at risk.

Men

  • Consider screening young men in high prevalence clinical settings or in populations with high burden of infection (e.g. MSM).
  • At least annually for sexually active men who have sex with men (MSM) and then very 3 to 6 months if at increased risk.

Individuals with HIV

  • For sexually active individuals, screen at first HIV evaluation, and at least annually thereafter.
  • More frequent screening might be appropriate depending on individual risk behaviors and the local epidemiology.

References

  1. 1.0 1.1 Screening Recommendations Referenced in Treatment Guidelines and Original Recommendation Sources. CDC. http://www.cdc.gov/std/tg2015/screening-recommendations.htm. Accessed on January 6th, 2016
  2. 2.0 2.1 Screening recommendation for chlamydia. UPSTF. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening?ds=1&s=chlamydia(2014). Acessed on September 8, 2016

Template:WikiDoc Sources